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additional palliative measures remain essential for adequate 
pain control. 
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Purpose/Objective: Graves’ Ophthalmopathy is the 
commonest extrathryoidal manifestation of Graves’ disease. 
The underlying pathogenesis is believed to be autoimmune-
related leading to excessive infiltration of lymphocytes and 
excessive production of hydrophilic glycosaminoglycans and 
subsequently expansion of retro-orbital tissues and 
enlargement of extraocular muscles. Treatment options 
include steroid therapy, corrective/decompressive surgery, 
radiation therapy or combination of these approaches. Our 
purpose is to investigate if retro-orbital irradiation with 
Inverse VMAT IMRT planning produced better target coverage 
and dose sparing to adjacent normal structures as compared 
with Forward IMRT and 3D conformal for patients with 
bilateral Graves’ Ophthalmopathy. 
Materials and Methods: Fourteen consecutive patients 
diagnosed with bilateral Graves’ Ophthalmopathy were 
prospectively recruited into this study. An individual Inverse 
VMAT IMRT planning, Forward IMRT and 3D conformal plan 
was created for each patient. Conformity Index (CI), 
Homogeneity Index (HI) and other dosimetric parameters of 
the targets and organs-at-risk (OAR) were compared between 
the different techniques. Statistical analysis was T-student. 
Results: CI generated by Inverse VMAT IMRT planning was 
superior to that produced by Forward IMRT and 3D conformal 
(p<.001 for both respectively). As expected Forward IMRT 
was superior to 3D conformal (p=.007). However the 
differences in the HI was not significant.  Inverse VMAT IMRT 
planning resulted in better OARs dose sparing (globe, lens, 
retina, lacrimal gland, optic nerve) with the exception of the 
optic chiasm that received a higher dose. The differences in 
the dose sparing of the OARs didn’t shown a significant 
difference when comparing Forward IMRT to 3D conformal. 
 Conclusions: Inverse VMAT IMRT planning is superior to 
Forward IMRT and 3D conformal for bilateral Graves’ 
Ophthalmopathy treatment in virtue of the benefit on the 
target coverage, better CI with similar HI, and better sparing 
of the OARs, despite an increase in treatment planning and 
delivery time, consumption of monitor units and a slightly 
increased but clinically negligible dose to some surrounding 
structures. 
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Purpose/Objective: To identify predictive factors of local 
control (LC) and develop a model for estimating tumor 
response in patients with cranial and extracranial 
oligometastases treated by hypofractionated stereotactic 
radiotherapy (SBRT/SRS). 
Materials and Methods: Clinical data from 79 patients who 
received hypofractionated SBRT/SRS for cranial and 
extracranial oligometastases (£ 5 lesions), with different 
primary tumor, primary histology, and metastatic lesions 
(lung, liver, brain, adrenal gland) were collected. Maximum 
local response was evaluated according to RECIST criteria. 
Univariate and multivariate analysis were performed to 
identify best significant predictors for local control. A dose-
response model estimating the maximum tumor response to 
treatment has been defined. 
Results: Main histological type was adenocarcinoma (62%). 
The most frequent primary tumor was colorectal cancer 
(44%); main oligometastastic sites were lung (58%), brain 
(22%), liver (15%), and adrenal gland (5%). The Median 
prescribed BED10 was 71.8 Gy (range, 45-100.8). The overall 
response rate was 61%. Median LC was 27.9 months, with a 2 
years LC rate of 60%. Univariate analysis defined 2 patient-
inherent factors indipendently related to LC: primary 
colorectal cancer (negative predictor, p=0.01), and the dose 
normalized to pretreatment lesion volume (ND; see equation) 
(positive predictor, p=0.02).Significant variables for LC on 
univariate analysis were tested in multivariate analysis. A 
logistic linear generalized model was fitted to data (figure). 
The model performed well for the ND (p=0.004). The 
evaluation method shows the Poisson model as good 
compromise between prediction power (TD50=16.1, 
g50=0.53; AIC=97.43, AUC=0.7045) and model simplicity. 
 
 
Figure: plot of the three dose-response models fitted to data, 
Logit (blue), LogLogit (red), Poisson (green). Confidence 
intervals for TCP and ND (BED/logVol) have been calculated 
by using bootstrapping 5000 sample series based on the initial 
dataset. 
Conclusions: The proposed model performed well, it was 
internal successfully validated, and showed the ability to 
predict a dose-response relationship between the prescribed 
dose, the lesion volume and the maximum response to 
hypofractionated stereotactic radiotherapy for 
oligometastatic patients. Future researches should be 
directed to test the model on more numerous and prognostic 
variables-based series of patients. 
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Purpose/Objective: Modern systemic tumour therapy 
ameliorates the prognosis of diverse malignancies. The 
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individual management of brain metastases using special 
radiotherapy protocols may improve both the patients’ 
survival and quality of life. We aimed at retrospectively 
studying the effects of low fraction dose whole-brain 
irradiation (WBRT) accompanied with simultaneous 
integrated boost (SIB). 
Materials and Methods: Between 2010 and 2013, 220 
patients with brain metastases were irradiated. Conventional 
WBRT (10 x 3 Gy) was delivered to 67 cases, who had a high 
number of metastasis. A SIB (15 x 0.7 Gy) dose in addition to 
WBRT (15 x 2.2 Gy) was applied in 153 cases with an average 
of 5 (1-14) metastases,. We assessed the overall survival (OS) 
in relation to the recursive partitioning analysis (RPA) value, 
the Karnofsky index and the metastasectomy (carried out or 
not) status of the patient. 
Results: The median OS of the WBRT-only and the WBRT+SIB 
groups was 3.7 and 6.4 months, respectively. In the 
WBRT+SIB group, the median OS was better in patients with 
RPA status 1 versus RPA status 2-3 (16.3 versus 5.3 months, 
p<0.0001), Karnofsky index ≥70% versus <70% (9.4 versus 4.4 
months, p<0.0001), and if metastasectomy was performed 
(8.0 versus 4.4 months, p<0.024). 
Conclusions: The differentiated treatment of patients with 
brain metastases according to the prognostic factors due to 
the higher cumulative dose of 3D-planned conformal 
radiotherapy delivered in a reasonable time may increase 
overall survival and possibly reduces the extent of late 
neurocognitive damage. 
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Purpose/Objective: There is an increasing evidence that 
multidisciplinary management of oligometastatic breast 
cancer with local therapy can improve disease control. The 
aim of our study is the assessment of safety and efficacy of 
SBRT in this selected subset of patients. 
Materials and Methods: Oligometastastic patients from 
breast cancer were treated with SBRT for 1-3 lung and liver 
lesions, in an observational study. Prescription dose ranged 
between 48 and 75 Gy in 3 or 4 consecutive fractions. 
Primary end-points were local control (LC). Secondary end-
point was toxicity, overall survival (OS) and progression-free 
survival (PFS). Local control was defined according to RECIST 
and PERCIST criteria. Toxicity was classified according to the 
Common Toxicity Criteria (CTC) version 3.0. 
Results: From February 2010 to November 2013, 29 patients 
were irradiated for a total number of 38 lesions. Twenty-one 
patients for a total of 27 liver lesions and 8 patients for a 
total of 11 lung lesions were treated. Median follow-up was 
20 (range 4 - 58) months. One and two- three years actuarial 
LC rate was 100% and 83% respectively. Complete response, 
partial response, stable disease and progression disease were 
detected in 24 (63%), 7 (19%), 4 (10%) and 3 (8%) lesions, 
respectively. Median overall survival (OS) was 39 months. 
Actuarial OS rate at 1, 2 and 3 years was 96%, 74 % and 60% 
respectively. Univariate analysis showed a correlation 
between OS and DFI > 5 years (p < 0.01). Median progression-
free survival (PFS) was 14 months, with a PFS rate at 1, 2 and 
3 years of 54%, 36% and 31% respectively. No patients 
experienced radiation-induced liver disease (RILD) or any 
grade >3 toxicity. 
Conclusions: SBRT is a safe and feasible alternative 
treatment of liver and lung oligometastases from breast 
cancer, in selected patients not amenable to surgery or other 
ablative treatments, with acceptable local control and 
survival rate. 
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Purpose/Objective: Long term follow up after re-irradiation 
of the spinal cord is lacking. The objective of the present 
study was therefore to evaluate the feasibility of health 
related quality of life measurements (HRQOL) measurements 
using the EQ5D-3L questionnaire following re-irradiation of 
metastatic spinal cord compression (MSCC). This is the first 
study to prospectively measure HRQOL in patients re-
irradiated for metastatic spinal cord compression 
Materials and Methods: During 2011 a total of 544 patients 
with acute symptoms of MSCC were enrolled in a prospective, 
consecutive cohort study. The Danish version of EQ5D was 
administered at baseline and 6, 12, 26 and 52 weeks after 
treatment. Nineteen patients received re-irradiation for 
progression at a previous irradiated site of the spine. A total 
of 15 patients answered one or more questionnaires; 7 
patients answered the questionnaire between the two 
treatments of radiotherapy and 8 patients answered the 
questionnaire after secondary treatment. No questionnaires 
were available in four patients.  
Results: Mean age was 63 years (range 43-81) with 3 men and 
5 women. Median survival after re-irradiation was 216 days 
(range 64-553). One patient was still alive at last follow-up. 
Diagnoses were two colon cancers, three lung cancers, one 
prostate cancer, one ovarian cancer and one bladder cancer. 
Median cumulative isoeffective prescribed dose in 2 Gy 
fractions was 62 Gy (range 47.7-84 Gy; α/β = 2). Distribution 
of answers is illustrated in Fig 1. In this strongly selected and 
small material answers for 'mobility' and 'pain' seems stable 
but 'usual activities' is declining until time of death. There 
were no reports of radiation induced myelopathy.  
